<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237844</url>
  </required_header>
  <id_info>
    <org_study_id>20191112</org_study_id>
    <nct_id>NCT04237844</nct_id>
  </id_info>
  <brief_title>Clinic Features and Outcome of BPD (SGBPD)</brief_title>
  <official_title>Clinic Features and Long-term Outcome of Different Subgroups of Brochopulmonary Dysplasia in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wang Jianhui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study described the perinatal high-risk factors and clinical manifestations of the
      children, and compared the high-risk factors, clinical manifestations and prognosis of BPD
      among different clinical subtypes by comparison between groups. BPD grading was performed
      using the 2018 grading standard to compare the distribution of I/II/III BPD among different
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 12 months after birth</time_frame>
    <description>Different subtype of BPD infants against the total BPD infants in corresponding group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious respiratory mobidities</measure>
    <time_frame>up to 18 months after birth</time_frame>
    <description>occurence of at least one of the following: tracheostomy, continued hospitalization for respiratory reasons at or beyond 50weeks PMA; continued oxygen supplement or respiratory support beyond 12months after birth; readmission for respiratory reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of first hospital stay</measure>
    <time_frame>up to 12 months after birth</time_frame>
    <description>days between admission and first discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days with oxygen supplement</measure>
    <time_frame>up to 12 months after birth</time_frame>
    <description>days during which the infants were given oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of Mechanical Ventilation</measure>
    <time_frame>up to 12 months after birth</time_frame>
    <description>days during which the infants were given mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>up to 18months after birth</time_frame>
    <description>the measure of infant's length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length</measure>
    <time_frame>up to 18months after birth</time_frame>
    <description>the measure of infant's weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>head circumference</measure>
    <time_frame>up to 18months after birth</time_frame>
    <description>the measure of infant's head circumference, which is the occipital-frontal circumference</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>no BPD</arm_group_label>
    <description>In preterm infants(GA&lt;32 weeks and hospital day&gt;14 days )，infants without BPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>classic BPD</arm_group_label>
    <description>In preterm infants(GA&lt;32 weeks and hospital day&gt;14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts &gt;25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPD after RDS</arm_group_label>
    <description>In preterm infants(GA&lt;32 weeks and hospital day&gt;14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2&lt;23% within 7 days, and the condition is aggravated to FiO2&gt;25%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed BPD</arm_group_label>
    <description>In preterm infants(GA&lt;32 weeks and hospital day&gt;14 days )，There is no RDS performance after birth, FiO2 lasts &lt;25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early, lethal BPD</arm_group_label>
    <description>In preterm infants(GA&lt;32 weeks and hospital day&gt;14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Premature infants born at &lt;32 weeks of gestational age and the hospitalization time ≥ 14
        days.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premature infants born at &lt;32 weeks of gestational age;

          2. hospitalization time ≥ 14 days;

          3. The clinical medical records are complete

        Exclusion Criteria:

          -  • 1) Children with congenital heart, lung malformation and definite chromosomal
             diseases; 2) children gave up treatment halfway; 3) corrected gestational age 36 weeks
             before death, the cause of death was confirmed as factors other than respiratory
             system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Shi</last_name>
    <role>Study Director</role>
    <affiliation>children's hospital of chongqiong Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967 Feb 16;276(7):357-68.</citation>
    <PMID>5334613</PMID>
  </reference>
  <reference>
    <citation>Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct;82(4):527-32.</citation>
    <PMID>3174313</PMID>
  </reference>
  <reference>
    <citation>Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9.</citation>
    <PMID>11401896</PMID>
  </reference>
  <reference>
    <citation>Laughon M, Allred EN, Bose C, O'Shea TM, Van Marter LJ, Ehrenkranz RA, Leviton A; ELGAN Study Investigators. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics. 2009 Apr;123(4):1124-31. doi: 10.1542/peds.2008-0862.</citation>
    <PMID>19336371</PMID>
  </reference>
  <reference>
    <citation>Streubel AH, Donohue PK, Aucott SW. The epidemiology of atypical chronic lung disease in extremely low birth weight infants. J Perinatol. 2008 Feb;28(2):141-8. Epub 2007 Dec 6.</citation>
    <PMID>18059466</PMID>
  </reference>
  <reference>
    <citation>Panickar J, Scholefield H, Kumar Y, Pilling DW, Subhedar NV. Atypical chronic lung disease in preterm infants. J Perinat Med. 2004;32(2):162-7.</citation>
    <PMID>15085893</PMID>
  </reference>
  <reference>
    <citation>Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH; Prematurity and Respiratory Outcomes Program. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc. 2015 Dec;12(12):1822-30. doi: 10.1513/AnnalsATS.201504-218OC.</citation>
    <PMID>26397992</PMID>
  </reference>
  <reference>
    <citation>Schmidt B. No End to Uncertainty about Inhaled Glucocorticoids in Preterm Infants. N Engl J Med. 2015 Oct 15;373(16):1566-7. doi: 10.1056/NEJMe1509243.</citation>
    <PMID>26465990</PMID>
  </reference>
  <reference>
    <citation>Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD, Thebaud B, Clyman RI, Collaco JM, Martin CR, Woods JC, Finer NN, Raju TNK. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr. 2018 Jun;197:300-308. doi: 10.1016/j.jpeds.2018.01.043. Epub 2018 Mar 16.</citation>
    <PMID>29551318</PMID>
  </reference>
  <reference>
    <citation>Steinhorn R, Davis JM, Göpel W, Jobe A, Abman S, Laughon M, Bancalari E, Aschner J, Ballard R, Greenough A, Storari L, Thomson M, Ariagno RL, Fabbri L, Turner MA; International Neonatal Consortium. Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development. J Pediatr. 2017 Dec;191:15-21.e1. doi: 10.1016/j.jpeds.2017.08.006.</citation>
    <PMID>29173299</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Wang Jianhui</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

